Department of Gynecological Minimal Invasive Center, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, No. 17, Qihelou Street, Dongcheng District, Beijing, 100006, China.
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Arch Gynecol Obstet. 2019 Nov;300(5):1399-1404. doi: 10.1007/s00404-019-05318-2. Epub 2019 Oct 1.
To evaluate the clinical and pathological features of endometrial cancer (EC) following breast cancer and to assess the effect of the breast cancer hormone receptor status on subsequent EC.
A retrospective study based on SEER data of EC patients with a history of breast cancer.
A total of 2142 cases met the inclusion criteria. Compared to that of the general population, the incidence of EC following estrogen receptor-positive (ER+) breast cancer and hormone receptor-negative (HR-) breast cancer increased by approximately 16-fold and 15-fold, respectively. Histologically, the proportions of type II EC following ER+ breast cancer, HR- breast cancer and primary EC were 39.6%, 39.4% and 31.2%, respectively (P < 0.001). The proportions of G3 ECs were 26.9%, 28.2% and 19.8%, respectively (P < 0.001). The proportion of patients who died from miscellaneous malignant tumors among EC patients following breast cancer was significantly higher than the proportion of patients among primary ECs. The overall survival rate was worse for EC patients with a history of breast cancer (P < 0.001). There were no significant differences between patients with EC following ER+ breast cancer and those with EC following HR- breast cancer with regard to stage, lymphatic metastasis, outcome or cause of death.
Compared to the general population, the incidence of EC in patients with breast cancer was increased markedly. Patients with EC following ER+ or HR- breast cancer shared the same clinicopathological features and prognoses. All patients need close monitoring regardless of breast cancer hormone receptor status.
评估乳腺癌后子宫内膜癌（EC）的临床和病理特征，并评估乳腺癌激素受体状态对随后发生 EC 的影响。
基于 SEER 数据的乳腺癌后 EC 患者的回顾性研究。
共有 2142 例符合纳入标准。与一般人群相比，雌激素受体阳性（ER+）乳腺癌和激素受体阴性（HR-）乳腺癌后 EC 的发病率分别增加了约 16 倍和 15 倍。从组织学上看，ER+乳腺癌、HR-乳腺癌和原发性 EC 后 II 型 EC 的比例分别为 39.6%、39.4%和 31.2%（P<0.001）。G3 ECs 的比例分别为 26.9%、28.2%和 19.8%（P<0.001）。乳腺癌后 EC 患者中死于各种恶性肿瘤的患者比例明显高于原发性 EC 患者。乳腺癌后 EC 患者的总生存率较差（P<0.001）。ER+乳腺癌后 EC 患者和 HR-乳腺癌后 EC 患者在分期、淋巴转移、结局或死亡原因方面均无显著差异。
与一般人群相比，乳腺癌患者 EC 的发病率显著增加。ER+或 HR-乳腺癌后发生 EC 的患者具有相同的临床病理特征和预后。无论乳腺癌激素受体状态如何，所有患者均需要密切监测。
